1. Introduction: The Evolution of Ovarian Cancer Care
Ovarian cancer remains a formidable clinical challenge, primarily because the lack of effective screening tools often results in diagnosis at advanced stages (FIGO Stage III-IV). Historically, Primary Cytoreductive Surgery (PCS) was the undisputed cornerstone of care. However, the 2025 ASCO guideline update reflects a significant paradigm shift: in the United States, there has been a substantial decline in PCS and a corresponding rise in Neoadjuvant Chemotherapy (NACT) followed by Interval Cytoreductive Surgery (ICS), which is now the most common upfront strategy.
Improving outcomes in this high-stakes environment requires more than a single intervention; it demands a sophisticated, multimodal treatment strategy that balances aggressive surgical intent with precision systemic therapy. This update provides an evidence-based framework for navigating the critical decision between PCS and NACT to optimize patient survival and quality of life.
2. The First Critical Step: Assessment and Genetic Testing
A comprehensive initial assessment is mandatory before treatment begins. This evaluation must be led by a gynecologic oncologist to determine surgical resectability and perioperative risk.
Initial Assessment Requirements:
- Imaging Excellence: Assessment must include CA-125 levels and a CT of the abdomen and pelvis with oral and intravenous contrast (including rectal contrast where appropriate). Chest imaging is required, with CT preferred.
- Refining Resectability: For cases where resectability is unclear, clinicians should utilize laparoscopy (highly reliable for predicting R0 feasibility), diffusion-weighted MRI, or FDG-PET scans.
- Histologic Differentiation: An endometrial biopsy should be considered to exclude advanced endometrial cancer, which can mimic the presentation of epithelial ovarian cancer (EOC).
The Testing Mandate
All patients with EOC must be offered germline and somatic testing at the time of diagnosis. This mandate extends beyond BRCA1 and BRCA2 to include other ovarian cancer susceptibility genes and Homologous Recombination (HR) status. Early identification of these variants is non-negotiable, as they dictate maintenance therapy eligibility and inform familial cancer risk.
3. The Decision Path: Primary Surgery (PCS) vs. Neoadjuvant Chemotherapy (NACT)
The choice of starting point must be individualized. While NACT is now more common, the guideline emphasizes that Complete Cytoreduction (R0)—the removal of all gross residual disease—remains the most powerful predictor of overall survival.
Choosing the Right Starting Point
| Patient Profile | Recommended Approach | Clinical Rationale |
|---|---|---|
| Medically fit for surgery AND high likelihood of achieving R0 resection. | Primary Cytoreductive Surgery (PCS) | R0 is the primary predictor of survival. Evidence from the SCORPION trial supports PCS as the standard for maximally resectable disease. |
| Medically fit for surgery BUT unlikely to achieve R0 resection. | Neoadjuvant Chemotherapy (NACT) | NACT increases the feasibility of R0 during later surgery. Trials like EORTC 55971 and CHORUS demonstrate non-inferiority to PCS in this cohort. |
| High perioperative risk profile (age, frailty, albumin <3.5, or comorbidities). | Neoadjuvant Chemotherapy (NACT) | NACT significantly reduces morbidity. The source confirms a lower rate of postoperative death (0.6% for NACT vs. 2.6% for PCS, $P=0.0439$). |
4. The NACT Journey: Protocol, Histology, and Timing
For patients initiating NACT, the following clinical directives ensure diagnostic accuracy and therapeutic intensity:
- Histologic Confirmation: NACT must be preceded by histologic confirmation of invasive cancer. Core biopsy is strongly preferred over fine-needle aspiration to ensure adequate tissue for molecular profiling. In extraordinary cases where biopsy is impossible, a CA-125:CEA ratio >25 may serve as a surrogate to exclude non-gynecologic origins.
- The Histology Warning: The evidence for NACT is strongest for high-grade serous and endometrioid histologies. Because low-grade serous and clear cell carcinomas exhibit lower chemotherapy response rates, PCS may be prioritized for these subtypes.
- The Regimen & Undertreatment Warning: A platinum-taxane doublet is the gold standard. Clinicians must avoid "undertreating" vulnerable patients; the GINECO/GCIG trial proved that single-agent carboplatin yields significantly worse survival than the doublet, even in elderly or frail populations.
- Timing and Monitoring: Response should be assessed via CA-125 and imaging after 3 cycles. The KELIM score (available via online tools) should be used to model chemosensitivity. ICS should occur after $\le$4 cycles of NACT for responders. Delaying surgery to cycle 5 or beyond is associated with declining survival.
5. Optimizing Surgical Outcomes: HIPEC and ICS
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) may be offered during ICS to improve disease-free and overall survival (Median OS 44.9 months vs. 33.3 months in the OVHIPEC-1 trial).
Criteria for HIPEC:
- FIGO Stage III disease.
- Stable disease or response after NACT, followed by ICS.
- Good performance status and adequate renal function (Creatinine Clearance $>30$ or serum Creatinine $<1.5$).
Safety Note: Nephrotoxicity Prevention HIPEC involves high-dose cisplatin (100 mg/m²), requiring strict multidisciplinary coordination. To prevent nephrotoxicity, clinicians must administer sodium thiosulfate (bolus at start, followed by continuous infusion). Avoid perioperative nephrotoxins like NSAIDs or contrast scans immediately following the procedure.
6. Beyond Surgery: Maintenance and Long-Term Strategy
- Post-ICS Chemotherapy: Patients should complete a total of six cycles (NACT + Post-ICS).
- Maintenance Therapy: Maintenance is the current standard of care and should be initiated based on trial-specific data:
- Olaparib + Bevacizumab: Recommended for HRD-positive tumors based on the PAOLA-1 trial.
- Olaparib Monotherapy: Strongly recommended for BRCA-mutated patients (SOLO1).
- Niraparib: An option for high-risk patients regardless of HRD status (PRIMA).
- Bevacizumab: Should be started at the second postoperative cycle to allow for wound healing.
- Managing Progression: If disease progresses during NACT (platinum-refractory), non-palliative surgery is generally contraindicated. Reconfirm the diagnosis via biopsy and prioritize clinical trials or palliative care over surgical intervention.
7. Bridging the Gap: Health Equity in Ovarian Cancer
Disparities in ovarian cancer care are a public health crisis. The African American Cancer Epidemiology Study (AACES) reveals a staggering gap: the 5-year overall survival for Black women is 49%, compared to 60% for White women.
The disparities are nuanced. While Black and Hispanic patients face lower rates of genetic testing and R0 resection due to barriers in affordability and specialist access, Asian populations present a unique profile: despite having lower documented testing rates, they often experience better survival outcomes than White patients, likely due to differences in age at diagnosis and tumor biology.
Adherence to clinical guidelines is the primary tool for eliminating these disparities. Ensuring every patient—regardless of race, insurance status, or geography—has access to a gynecologic oncologist and molecular testing is essential to closing the survival gap.
8. Conclusion: Empowered Decision-Making
The 2025 ASCO update underscores that ovarian cancer care is no longer a "one-size-fits-all" surgical specialty, but a precision-driven multidisciplinary field.
Top 3 Takeaways for Patients and Providers:
- R0 is the Goal: Every patient must be evaluated by a gynecologic oncologist to maximize the chances of a complete (R0) resection.
- Molecular Profiling is Mandatory: Germline and somatic testing for BRCA and HRD must happen at diagnosis to unlock maintenance therapy benefits.
- NACT Requires Precision: When NACT is chosen, use a doublet regimen, monitor chemosensitivity via KELIM, and perform ICS by the fourth cycle.
Effective care relies on shared decision-making. By applying these evidence-based standards, we ensure that every patient receives a treatment plan as sophisticated as the disease we are fighting.